Key Points
- Director Gilla Kaplan sold 14,295 shares of Tyra Biosciences on March 25 at an average price of $36.97 for a total of $528,486.15, reducing her stake by 33.61% to 28,231 shares; the trade was disclosed in an SEC filing.
- TYRA shares opened at $36.29, trade in a one‑year range of $6.42–$39.15, have a market cap of $1.95 billion and a negative P/E of -18.05, and the company recently missed quarterly EPS (‑$0.57 vs. ‑$0.54 est.).
- Institutional ownership is 84.14% with several funds upping positions, and analysts hold a consensus "Moderate Buy" rating with a $44.67 price target (individual targets raised as high as $56 by Piper Sandler).
Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of the business's stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $36.97, for a total transaction of $528,486.15. Following the completion of the sale, the director directly owned 28,231 shares of the company's stock, valued at $1,043,700.07. The trade was a 33.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Tyra Biosciences Stock Performance
Shares of TYRA stock opened at $36.29 on Friday. Tyra Biosciences, Inc. has a one year low of $6.42 and a one year high of $39.15. The company's 50-day simple moving average is $32.90 and its 200-day simple moving average is $23.77. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -18.05 and a beta of 1.06.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.03). As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in TYRA. Millennium Management LLC boosted its holdings in shares of Tyra Biosciences by 28.2% during the first quarter. Millennium Management LLC now owns 404,165 shares of the company's stock valued at $3,759,000 after acquiring an additional 89,024 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Tyra Biosciences by 21.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock worth $725,000 after acquiring an additional 13,896 shares during the period. Woodline Partners LP bought a new stake in Tyra Biosciences in the 1st quarter valued at about $931,000. Jane Street Group LLC acquired a new position in Tyra Biosciences during the 1st quarter valued at about $324,000. Finally, Geode Capital Management LLC boosted its stake in Tyra Biosciences by 9.8% during the 2nd quarter. Geode Capital Management LLC now owns 567,126 shares of the company's stock valued at $5,428,000 after purchasing an additional 50,836 shares during the period. 84.14% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on TYRA shares. HC Wainwright upped their price target on Tyra Biosciences from $30.00 to $45.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Barclays initiated coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They set an "overweight" rating for the company. Piper Sandler increased their target price on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an "overweight" rating in a report on Friday, March 20th. Wall Street Zen downgraded shares of Tyra Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, January 24th. Finally, Cantor Fitzgerald began coverage on shares of Tyra Biosciences in a research report on Tuesday, February 24th. They set an "overweight" rating for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.67.
Get Our Latest Stock Report on Tyra Biosciences
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
